Lipum AB (ST:LIPUM) — Market Cap & Net Worth
Market Cap & Net Worth: Lipum AB (LIPUM)
Lipum AB (ST:LIPUM) has a market capitalization of $32.76 Million (Skr304.40 Million) as of September 18, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #23544 globally and #448 in its home market, demonstrating a 1.77% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lipum AB's stock price Skr14.35 by its total outstanding shares 21212438 (21.21 Million). Also see LIPUM current and non-current assets for a full breakdown of the balance sheet.
Lipum AB Market Cap History: 2021 to 2026
Lipum AB's market capitalization history from 2021 to 2026. Data shows change from $42.23 Million to $32.76 Million (-8.94% CAGR). Also see Lipum AB (LIPUM) cash conversion ratio for how efficiently the company converts equity into cash flow.
Index Memberships
Lipum AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.31 Billion | 0.21% | #81 of 281 |
Weight: Lipum AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Lipum AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lipum AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check LIPUM stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
280.83x
Lipum AB's market cap is 280.83 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $42.23 Million | $-197.00 | -$52.41 Million | -214374.35x | N/A |
| 2023 | $14.88 Million | $53.00K | -$37.18 Million | 280.83x | N/A |
Competitor Companies of LIPUM by Market Capitalization
Companies near Lipum AB in the global market cap rankings as of September 18, 2026. Review LIPUM intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Lipum AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Lipum AB Historical Marketcap From 2021 to 2026
Between 2021 and today, Lipum AB's market cap moved from $42.23 Million to $ 32.76 Million, with a yearly change of -8.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr32.76 Million | -1.71% |
| 2025 | Skr33.33 Million | +21.67% |
| 2024 | Skr27.39 Million | +84.05% |
| 2023 | Skr14.88 Million | -53.26% |
| 2022 | Skr31.85 Million | -24.59% |
| 2021 | Skr42.23 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Lipum AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $32.76 Million USD |
| MoneyControl | $32.76 Million USD |
| MarketWatch | $32.76 Million USD |
| marketcap.company | $32.76 Million USD |
| Reuters | $32.76 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lipum AB
Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. The company develops SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. It has a collaboration with NorthXBiologies for production of SOL-116 setatt; and a… Read more